Wolfe Research started PRA Health with a Peer Perform rating and $112 price target, stating that the firm is cautious on softening gross bookings in the second half of 2018 and the revenue ramp and margin improvement imbedded in guidance for 2019.
Tuesday, April 2, 2019
Syneos Health initiated with a Peer Perform at Wolfe Research
Wolfe Research started Syneos Health with a Peer Perform rating and $53 price target, stating that while the stock trades at a meaningful discount to peers the firm doesn’t have the conviction to step in given that results and stock performance to date have been highly volatile.
LabCorp initiated at Wolfe Research
LabCorp initiated with an Underperform at Wolfe Research. Wolfe Research started LabCorp with an Underperform rating and $150 price target, citing concerns about the 2021 impact of PAMA and exposure to patient collections.
https://thefly.com/landingPageNews.php?id=2887449
https://thefly.com/landingPageNews.php?id=2887449
Clovis: Interim Results of Rubraca® (rucaparib) Phase 2 in Pancreatic Cancer
- Interim data from an investigator-initiated study in first-line maintenance setting for advanced pancreatic cancer suggest that Rubraca provides disease control with no new safety signals in 19 evaluable platinum-sensitive patients with germline BRCA1, germline or somatic BRCA2, or germline PALB2 mutations
- Clovis is evaluating a potential clinical and regulatory path forward for Rubraca in pancreatic cancer
- Nonclinical studies of rucaparib and lucitanib in multiple solid tumor types and Rubraca Trials in Progress posters also presented at AACR 2019
BioRad: Innovative Lyme Disease Diagnostic Test with FDA Clearance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.
Lyme disease is the most common tick-borne illness in the United States. Many signs and symptoms of the disease are similar to other conditions so diagnosis can be challenging; however, individuals immediately treated for the disease usually recover rapidly and completely. The BioPlex 2200 Lyme Total Assay can simultaneously detect multiple targets, providing laboratories valuable information in the early stages of Lyme disease so patients are able to receive treatment as quickly as possible.
“The addition of the BioPlex 2200 Lyme Total assay broadens our BioPlex 2200 System infectious disease menu, offering laboratories the ability to detect Lyme disease at an early stage and thus fulfilling an important medical need in the management of Lyme disease,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group.
The release of the BioPlex 2200 Lyme Total assay is the latest offering in Bio-Rad’s infectious disease menu for the BioPlex 2200 System, an automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.
Vistagen Positive Pilot Data Position Neuroactive Nasal Spray for Phase 3
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, announced today additional results from a positive pilot Phase 3 study of PH94B, a potential first-in-class neuroactive nasal spray shown to be effective on an as-needed (PRN) basis for treatment of social anxiety disorder (SAD).
The new data were presented in a poster session at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference in Chicago.
In the 22-patient, four-week, randomized, double blind, placebo-controlled pilot Phase 3 crossover study, subjects receiving PH94B had a significantly greater decrease in average peak Subjective Units of Distress scores compared to placebo within one week of treatment.1 There was also a significantly greater decrease in Liebowitz Social Anxiety Scale (LSAS) avoidance scores for subjects who received PH94B first, before crossing over to placebo. Administered at microgram doses and consistent with results from prior Phase 2 studies, PH94B’s safety profile was excellent, with no serious adverse events. VistaGen is currently preparing for pivotal Phase 3 development of PH94B as a novel first-line PRN treatment for SAD, with Dr. Michael Liebowitz, developer of the LSAS, a widely-used primary outcome measure in SAD for both clinical research and for evaluation in clinical practice, acting as Principal Investigator for the study.
WellCare Expands Medicaid Programs to 3 Additional NY Counties
WellCare Health Plans, Inc. (NYSE: WCG), a leading provider of Medicaid, Medicare and Prescription Drug programs, announced today that the New York Department of Health has approved the expansion of WellCare of New York, Inc. into three additional counties. The approval adds Broome, Richmond, and Suffolk counties to the company’s Medicaid Managed Care, Child Health Plus and Essential Plan programs, effectively immediately.
The expansion complements WellCare’s existing 16-county coverage area in Nassau, Kings, Queens, Manhattan, Bronx, Erie , Niagara, Steuben, Schuyler, Albany, Schenectady, Rensselaer, Duchess, Orange, Ulster and Rockland for Medicaid, Child Health Plus and Essential Plan programs.
“We are excited to have the opportunity to serve more members in New York, in partnership with the State, the new communities we are entering, and our providers,” said John J. Burke, president of WellCare of New York. “During the past several months, our team has diligently worked to build partnerships with providers and stakeholders in these new counties, and we look forward to helping more communities achieve better, healthier lives.”
WellCare has partnered with the New York Department of Health since 2002 to provide quality care for children, families, seniors and the disabled through Medicaid programs.
As of Dec. 31, 2018, WellCare serves approximately 295,000 members in New York, including 155,000 Medicaid members, 89,000 Medicare Advantage plan members and 52,000 Medicare Prescription Drug Plan members.
Subscribe to:
Posts (Atom)